Short term outcome of neonatal venous thromboembolism in anticoagulated versus observed patients.
Research article published in Thrombosis research (2024)
Abstract
BACKGROUND: Advancements in the medical field and increased survival of premature infants have led to a rise of venous thromboembolism (VTE) in neonates. Neonatal hemostasis exists in a delicate balance with a propensity towards pro-coagulation. Current recommendations include careful observation, therapeutic anti-coagulation and in some cases thrombolysis. We hypothesize that a sub-group of neonates may not require anti-coagulation and could be safely observed thus reducing their risk of bleeding complications. METHODS: We conducted a retrospective chart review of patients with VTE admitted to the neonatal intensive care unit at the Oklahoma University Children's Hospital from October 2009-October 2019. Patients were selected if they had an ICD-9 or ICD-10 code specific for a VTE or if screening with CPT codes for diagnostic imaging including echocardiogram, venous dopplers and computed topographic/magnetic resonance venogram revealed the word 'thrombus', 'clot' or 'venous thromboembolism'. Data were collected about demographics, medical history, co-morbidities, thrombosis characteristics, treatment and outcome. RESULTS: A total of 211 patients were screened and 119 patients were eligible and included in the study. The majority of patients (85 %) had a central venous catheter (CVC) associated VTE. Two-thirds of patients (n = 81, 68 %) received therapeutic anti-coagulation while one-third (n = 38, 32 %) were observed. The group that received anticoagulation had a significantly older age at diagnosis and had a higher frequency of bacteremia, congenital heart disease and presence of symptoms. There was no difference in the odds of complete resolution between patients who were treated with therapeutic anti-coagulation and those that were observed (OR: 1.37, 95 % CI: 0.59-3.20, p-value: 0.47). Univariate analysis revealed maternal preeclampsia (OR: 0.2, 95 % CI: 0.05-0.82, p-value = 0.025), maternal history of chronic hypertension (OR: 0.17, 95 % CI: 0.04-0.68, p-value = 0.01), and presence of complete occlusion (OR = 0.37, 95 % CI: 0.15-0.91, p-value = 0.03) significantly reduced the odds of complete resolution. Furthermore, having a VTE related to a CVC in an extremity versus an ECMO cannula or cardiac catheterization significantly improved the odds of VTE resolution (OR = 5.94, 95 % CI: 1.30-27.20, p-value = 0.022). Using a stepwise regression model, maternal history of chronic hypertension remained significant for a reduced odds of VTE resolution (OR: 0.14, 95 % CI 0.025-0.73, p-value: 0.02). CONCLUSIONS: The short-term outcome of neonatal VTE does not seem to differ between those that were anticoagulated and those that were observed with serial imaging.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Advancements in the medical field and increased survival of premature infants have led to a rise of venous thromboembolism (VTE) in neonates. Neonatal hemostasis exists in a delicate balance with a propensity towards pro-coagulation. Current recommendations include careful observation, therapeutic anti-coagulation and in some cases thrombolysis.
Warum dies für die Hirudotherapie relevant ist
Diese monozentrische retrospektive Aktenauswertung verglich 119 Neugeborene mit venöser Thromboembolie (VTE), von denen etwa zwei Drittel eine therapeutische Antikoagulation erhielten und ein Drittel beobachtet wurde, und fand keinen statistisch signifikanten Unterschied in der Wahrscheinlichkeit einer vollständigen Thrombusauflösung zwischen der behandelten und der beobachteten Gruppe (OR 1,37, 95% CI 0,59–3,20). Der Befund ist relevant für das umfassendere Bild der Antikoagulations-Evidenz, das die Wirkstoffforschungs-Rationale der Hirudotherapie umrahmt, und unterstreicht, dass das Nutzen-Risiko-Verhältnis der Antikoagulation selbst in vulnerablen Populationen noch nicht abschließend definiert ist; er untersucht weder Blutegel noch ein aus Blutegeln gewonnenes Molekül. Als retrospektive, beobachtende Studie an einer einzigen Institution ist er nur hypothesengenerierend, anfällig für einen Selektionsbias (kränkere oder ältere Säuglinge wurden antikoaguliert) und kann nicht belegen, dass ein Verzicht auf Antikoagulation sicher ist; er sollte nicht als klinische Unterstützung für die Hirudotherapie gelesen werden.
Zitation
Short term outcome of neonatal venous thromboembolism in anticoagulated versus observed patients.
Beg KA et al. · Thrombosis research, 2024
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026